- TP53 variants in p53 signatures and the clonality of STICs in RRSO samples
-
Akahane T, Masuda K, Hirasawa A, Kobayashi Y, Ueki A, Kawaida M, Misu K, Nakamura K, Nagai S, Chiyoda T, Yamagami W, Hayashi S, Kataoka F, Banno K, Sugano K, Okita H, Kosaki K, Nishihara H, Aoki D
- KMID: 2537895
- J Gynecol Oncol.
- 2022 Jul;33(4):e50.
- doi: 10.3802/jgo.2022.33.e50
Objective Precursor lesions may be identified in fallopian tube tissue after risk-reducing salpingo-oophorectomy (RRSO) in patients with pathogenic variants of BRCA1/2. Serous tubal intraepithelial carcinoma (STIC) is considered a precursor of... -
- CITED
-
- Close
- SHARE
-
- Close
- Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma
-
Iijima M, Okonogi N, Nakajima N, Morokoshi , Kanda H, Yamada T, Kobayashi , Banno K, Wakatsuki , Yamada S, Kamada T, Aoki D, Hasegawa S
- KMID: 2470870
- J Gynecol Oncol.
- 2020 Mar;31(2):e19.
- doi: 10.3802/jgo.2020.31.e19
OBJECTIVE: Programmed cell death-ligand 1 (PD-L1) is expressed in tumor cells and has been shown to predict clinical outcomes of several types of malignancies. The aim of this study was... -
- CITED
-
- Close
- SHARE
-
- Close
- LAMC1 is a prognostic factor and a potential therapeutic target in endometrial cancer
-
Kunitomi H, Kobayashi , Wu RC, Takeda T, Tominaga E, Banno K, Aoki D
- KMID: 2470864
- J Gynecol Oncol.
- 2020 Mar;31(2):e11.
- doi: 10.3802/jgo.2020.31.e11
OBJECTIVE: With the emerging significance of genetic profiles in the management of endometrial cancer, the identification of tumor-driving genes with prognostic value is a pressing need. The LAMC1 gene, encoding... -
- CITED
-
- Close
- SHARE
-
- Close
- Current state and outlook for drug repositioning anticipated in the field of ovarian cancer
-
Kobayashi , Banno K, Kunitomi H, Tominaga E, Aoki D
- KMID: 2429579
- J Gynecol Oncol.
- 2019 Jan;30(1):e10.
- doi: 10.3802/jgo.2019.30.e10
Ovarian cancer is the seventh most common cancer and the eighth most common cause of cancer mortality in women. Although standard chemotherapy is the established treatment for ovarian cancer, the... -
- CITED
-
- Close
- SHARE
-
- Close
- Screening for Lynch syndrome using risk assessment criteria in patients with ovarian cancer
-
Takeda T, Tsuji K, Banno K, Yanokura M, Kobayashi , Tominaga E, Aoki D
- KMID: 2409933
- J Gynecol Oncol.
- 2018 May;29(3):e29.
- doi: 10.3802/jgo.2018.29.e29
OBJECTIVE: Lynch syndrome is a cancer predisposition syndrome caused by germline mutation of DNA mismatch repair (MMR) genes. Lynch syndrome only causes about 0.4% of cases of ovarian cancer, which... -
- CITED
-
- Close
- SHARE
-
- Close
- Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
-
Yamagami W, Susumu N, Makabe T, Sakai K, Nomura H, Kataoka F, Hirasawa A, Banno K, Aoki D
- KMID: 2404016
- J Gynecol Oncol.
- 2018 Mar;29(2):e21.
- doi: 10.3802/jgo.2018.29.e21
OBJECTIVE: Reports on the repeated administration of medroxyprogesterone acetate (MPA) for intrauterine recurrence after fertility-preserving therapy for atypical endometrial hyperplasia (AEH) and early grade 1 endometrioid carcinoma (G1) are lacking.... -
- CITED
-
- Close
- SHARE
-
- Close
